Composition, form of production and packaging
? The cream for external use is yellowish white, viscous, with a smell of camphor and menthol.
glucosamine hydrochloride 3 mg (0.3%)
chondroitin sulfate 8 mg (0.8%)
camphor 32 mg (3.2%)
peppermint oil 9 mg (0.9%)
[PRING] Aloe tree, cetyl alcohol, lanolin, methyl parahydroxybenzoate, macrogol 100 stearate, propylene glycol, propyl parahydroxybenzoate, purified water, dimethicone.
28.4 g - plastic tubes (1) - packs of cardboard.
56.7 g - plastic tubes (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
The product description was approved by the manufacturer for the 2009 print edition.
The drug with improves the regeneration of cartilaginous tissue and anti-inflammatory action for external use.
Chondroitin sulfate is a high molecular weight mucopolysaccharide, which is involved in the construction of cartilaginous tissue. Reduces the activity of enzymes that destroy articular cartilage and stimulates its regeneration. In the early stages of the inflammatory process, chondroitin sulfate reduces its activity and thus slows the degeneration of the cartilaginous tissue. Helps reduce the intensity of pain syndrome, improve joint function, reduces the need for NSAIDs.
Glucosamine hydrochloride has chondroprotective properties, reduces the glycosaminoglycan deficiency in the body, takes part in the biosynthesis of proteoglycans and hyaluronic acid. Glucosamine hydrochloride selectively acts on the articular cartilage, is a specific substrate and stimulator for the synthesis of hyaluronic acid and proteoglycans, inhibits the formation of superoxide radicals and enzymes that damage the cartilaginous tissue (collagenase and phospholipase).
Camphor with local application irritates the sensitive nerve endings of the skin and subcutaneous tissues, expands the surface vessels, causes a feeling of heat, improves blood supply to the skin and subcutaneous tissues, and has a moderate antiseptic effect.
Peppermint oil with local application has a moderate antiseptic, anti-inflammatory, anesthetic and distracting effect.
Data on the pharmacokinetics of Teraflex M are not available.
- degenerative-dystrophic diseases of the joints and spine (including osteoarthritis and osteochondrosis).
A strip of cream 2-3 cm long is applied to the skin over the lesion site 2-3 times / day and rubbed to full suction.
Allergic reactions are possible .
- damage to the skin;
- increased individual sensitivity to the components of the drug.
Caution should be given to children.
PREGNANCY AND LACTATION
Clinical data on the effectiveness and safety of the drug during pregnancy and during breastfeeding are absent.
Teraflex M should not be applied to damaged areas of the skin.
Overdose of Teraflex M is not described. In case of overdose, symptomatic treatment is recommended.
Data on the effect of topical use of Teraflex M cream on the pharmacodynamics and pharmacokinetics of other drugs are not available.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry, protected from light, out of reach of children at a temperature of no higher than 27 В° C. Shelf life - 2 years.